Should I buy or sell Clene stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLNN shares. View CLNN analyst ratings or view top-rated stocks .

What is Clene's stock price target for 2024?

6 brokers have issued 12 month price objectives for Clene's stock. Their CLNN share price targets range from $4.00 to $13.00. On average, they expect the company's share price to reach $7.80 in the next twelve months. This suggests a possible upside of 1,822.6% from the stock's current price. View analysts price targets for CLNN or view top-rated stocks among Wall Street analysts .

How have CLNN shares performed in 2023?

Clene's stock was trading at $1.00 on January 1st, 2023. Since then, CLNN shares have decreased by 59.4% and is now trading at $0.4057. View the best growth stocks for 2023 here .

When is Clene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024. View our CLNN earnings forecast .

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) released its earnings results on Tuesday, November, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.08. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.14 million. Clene had a negative trailing twelve-month return on equity of 322.31% and a negative net margin of 5,624.65%.

Who are Clene's major shareholders?

Clene's stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (4.52%), Vivo Capital LLC (2.06%), Worth Venture Partners LLC (1.09%), Silverarc Capital Management LLC (0.39%), AE Wealth Management LLC (0.13%) and Kepos Capital LP (0.10%). Insiders that own company stock include Alison Mosca, David J Matlin, David J Matlin , General Resonance Llc, John Henry Stevens, Jonathon Gay, Robert Dee Etherington and Robert Glanzman. View institutional ownership trends .

How do I buy shares of Clene?

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Clene Stock Price, News & Analysis (NASDAQ:CLNN)

$0.41

+0.01 (+1.28%)

(As of 12:25 PM ET)

Compare

Today's Range: $0.40
▼
$0.42
50-Day Range: $0.38
▼
$0.54
52-Week Range: $0.36
▼
$1.99

Volume: 211,009 shs
Average Volume: 579,810 shs
Market Capitalization: $52.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.80

Clene MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,822.6% Upside
$7.80 Price Target
Short Interest: Healthy
0.45% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$102,501 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.28) to ($0.34) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

381st out of 958 stocks

Pharmaceutical Preparations Industry

131st out of 393 stocks

3.5

Analyst's Opinion

Consensus Rating
Clene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.80, Clene has a forecasted upside of 1,822.6% from its current price of $0.41.
Amount of Analyst Coverage
Clene has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.45% of the outstanding shares of Clene have been sold short.
Short Interest Ratio / Days to Cover
Clene has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Clene has recently decreased by 15.36%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Clene does not currently pay a dividend.
Dividend Growth
Clene does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLNN.

0.6

News and Social Media Coverage

Search Interest
Only 16 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
11 people have added Clene to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Clene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,501.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
26.60% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 3.87% of the stock of Clene is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Clene are expected to decrease in the coming year, from ($0.28) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Clene is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Clene is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Clene has a P/B Ratio of 10.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Clene Stock (NASDAQ:CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

CLNN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLNN Stock News Headlines

November 23, 2023 | finance.yahoo.com

Clene Capitalizing on Promising Chemical and Therapeutic Properties of Nanocrystals

November 15, 2023 | finance.yahoo.com

Insider Spends US$103k Buying More Shares In Clene

December 7, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 9, 2023 | finance.yahoo.com

Clene Announces Q3 2023 Financial Results, Operating Highlights

November 9, 2023 | markets.businessinsider.com

Benchmark Co. Keeps Their Buy Rating on Clene (CLNN)

November 7, 2023 | msn.com

Clene GAAP EPS of -$0.02, revenue of $0.11M

November 7, 2023 | finance.yahoo.com

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

November 7, 2023 | finance.yahoo.com

Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45.

December 7, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 7, 2023 | finance.yahoo.com

Clene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45. ...

October 31, 2023 | finance.yahoo.com

Clene Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis

October 26, 2023 | finance.yahoo.com

Clene Inc. (CLNN) Interactive Stock Chart - Yahoo Finance

October 26, 2023 | finance.yahoo.com

Clene Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS

October 19, 2023 | finance.yahoo.com

Clene 'Innovates' Investigational Drug With Patented Nanotechnology

October 17, 2023 | finance.yahoo.com

Clene Applies Patented Nanotechnology to Development of CNM-Au8(R), Its Investigational Drug for ALS

October 11, 2023 | finance.yahoo.com

Clene CEO Featured in Latest Episode of The Bell2Bell Podcast

October 7, 2023 | markets.businessinsider.com

Promising Potential of Clene’s CNM-Au8 in Neurological Treatment Boosts Stock Buy Rating

October 6, 2023 | msn.com

Clene (CLNN) Price Target Increased by 6.29% to 6.32

October 5, 2023 | markets.businessinsider.com

Promising Future for Clene’s Stock: NIH Grant and Encouraging Clinical Results Boost Confidence

October 5, 2023 | finance.yahoo.com

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

September 29, 2023 | finance.yahoo.com

Clene Investigational Drug Focus of Study Published in Peer-Reviewed Journal

September 29, 2023 | finance.yahoo.com

Clene Inc. Is 'One to Watch'

September 29, 2023 | theglobeandmail.com

Clene (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

September 28, 2023 | stockhouse.com

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

September 28, 2023 | finance.yahoo.com

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

September 27, 2023 | finance.yahoo.com

Clene Releases Significant Long-Term Survival Improvement Data from ALS Trial

September 26, 2023 | markets.businessinsider.com

Promising Efficacy and Safety Data for Clene’s CNM-Au8 Spurs Buy Rating Recommendation: Anticipating Accelerated Approval and NDA Filing by 2024

See More Headlines

Receive CLNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/11/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CLNN
CUSIP: N/A
CIK: 1822791
Web: clene.com
Phone: 801-676-9695
Fax: N/A
Employees: 75
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.80
High Stock Price Target: $13.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +1,850.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,920,000.00
Net Margins: -5,624.65%
Pretax Margin: -5,624.65%
Return on Equity: -322.31%
Return on Assets: -67.52%

Debt

Debt-to-Equity Ratio: 0.78
Current Ratio: 3.04
Quick Ratio: 3.04

Sales & Book Value

Annual Sales: $718,000.00
Price / Sales: 71.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.04 per share
Price / Book: 10.00

Miscellaneous

Outstanding Shares: 128,416,000
Free Float: 94,257,000
Market Cap: $51.37 million
Optionable: Not Optionable
Beta: 0.53

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Robert Etherington MBA (Age 56)
CEO, President & Director
Comp: $590.98k
Mr. Morgan R. Brown CPA (Age 55)
M.B.A., Chief Financial Officer
Comp: $374.05k
Mr. Mark G. Mortenson ESQ. (Age 65)
Chief Science Officer
Comp: $482.98k
Mr. Jerry Miraglia J.D.
General Counsel & Corporate Secretary
Mr. Michael T. Hotchkin
Chief Development Officer
Ms. Mary Anne Mcneil
Head of Human Resources
Dr. Benjamin M. Greenberg M.D.
M.H.S., Head of Medical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CLNN Stock Analysis - Frequently Asked Questions

Should I buy or sell Clene stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLNN shares.
View CLNN analyst ratings or view top-rated stocks.
What is Clene's stock price target for 2024?: 6 brokers have issued 12 month price objectives for Clene's stock. Their CLNN share price targets range from $4.00 to $13.00. On average, they expect the company's share price to reach $7.80 in the next twelve months. This suggests a possible upside of 1,822.6% from the stock's current price.
View analysts price targets for CLNN or view top-rated stocks among Wall Street analysts.
How have CLNN shares performed in 2023?: Clene's stock was trading at $1.00 on January 1st, 2023. Since then, CLNN shares have decreased by 59.4% and is now trading at $0.4057.
View the best growth stocks for 2023 here.
When is Clene's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our CLNN earnings forecast.

How were Clene's earnings last quarter?: Clene Inc. (NASDAQ:CLNN) released its earnings results on Tuesday, November, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.08. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.14 million. Clene had a negative trailing twelve-month return on equity of 322.31% and a negative net margin of 5,624.65%.
Who are Clene's major shareholders?: Clene's stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (4.52%), Vivo Capital LLC (2.06%), Worth Venture Partners LLC (1.09%), Silverarc Capital Management LLC (0.39%), AE Wealth Management LLC (0.13%) and Kepos Capital LP (0.10%). Insiders that own company stock include Alison Mosca, David J Matlin, David J Matlin, General Resonance Llc, John Henry Stevens, Jonathon Gay, Robert Dee Etherington and Robert Glanzman.
View institutional ownership trends.
How do I buy shares of Clene?: Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLNN) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Clene Stock Price, News & Analysis (NASDAQ:CLNN)

Clene MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Clene Stock (NASDAQ:CLNN)

CLNN Stock Price History

CLNN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CLNN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™